After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...